Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 18/20 | 0.51 |
| ▸ | HRH2 | P25021 | 3/20 | 0.45 |
| ▸ | HRH1 | P35367 | 3/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10261001 | 0.89 | HRH3 (0.67) | HRH3CHRM2SLC6A2SLC6A3 | |
| SCHEMBL10258423 | 0.88 | HRH3 (0.66) | HRH3HRH2HRH1 | |
| SCHEMBL10267637 | 0.86 | HRH3 (0.52) | HRH3HRH2HRH1 | |
| SCHEMBL10259496 | 0.86 | HRH3 (0.52) | HRH3HRH2HRH1 | |
| SCHEMBL10260714 | 0.84 | HRH3 (0.55) | HRH3HRH2HRH1 | |
| SCHEMBL13141136 | 0.82 | HRH3 (0.53) | HRH3HRH2HRH1HRH4 | |
| SCHEMBL1372912 | 0.80 | HRH3 (0.78) | HRH3HRH2HRH1 | |
| SCHEMBL13572238 | 0.80 | HRH3 (0.78) | HRH3HRH2HRH1 | |
| SCHEMBL10258257 | 0.77 | HRH3 (0.71) | HRH3CHRM2SLC6A2SLC6A3 | |
| SCHEMBL10260710 | 0.72 | HRH3 (0.65) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207168-B2 | Pyridazinone derivatives | CEPHALON, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-20100280007-A1 | Pyridazinone Derivatives | CEPHALON, INC. (US) | 2010-11-04 | — | — | US | disclosed |
| US-20100273779-A1 | Pyridazinone Derivatives | CEPHALON, INC. (US) | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280007-A1 | Pyridazinone Derivatives | HRH3, HNMT, HRH4 | HRH3 1/4885HRH2 7/4885HRH1 5/4885 |
| US-20100273779-A1 | Pyridazinone Derivatives | HRH3, HNMT, HRH4 | HRH3 1/4885HRH2 7/4885HRH1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.